Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Sigrid S. Skånland, Jennifer R. Brown
Haematologica (2022) Vol. 108, Iss. 1, pp. 9-21
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death
Maria Elena Mantione, Miriam Meloni, Ilenia Sana, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 3
Open Access | Times Cited: 20
Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions
Hongyao Li, Xiang Wen, Yueting Ren, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives
Toby A. Eyre, John C. Riches
Cancers (2023) Vol. 15, Iss. 9, pp. 2596-2596
Open Access | Times Cited: 17
PI3K inhibitors in hematology: When one door closes…
Sigrid S. Skånland, Klaus Okkenhaug, Matthew S. Davids
Clinical Cancer Research (2024) Vol. 30, Iss. 17, pp. 3667-3675
Closed Access | Times Cited: 5
Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity
Aboli Bhingarkar, Yuyin Wang, Keito Hoshitsuki, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Targeting PI3Kγ in cancer
Giuliana P. Mognol, Anghesom Ghebremedhin, Judith A. Varner
Trends in cancer (2025)
Open Access
A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
Johanne U. Hermansen, Yanping Yin, Aleksandra Urban, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 10
TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas
Siyue Lou, Fanli Zheng, Yongmei Tang, et al.
Life Sciences (2024) Vol. 347, pp. 122662-122662
Closed Access | Times Cited: 3
Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia
Yongmei Tang, Yanan Zheng, Xueping Hu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6638-6657
Closed Access | Times Cited: 2
Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents
Andrea Galitzia, Monica Maccaferri, Francesca Romana Mauro, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 1996-1996
Open Access | Times Cited: 2
Lysine-Targeted Covalent Inhibitors of PI3Kδ Synthesis and Screening by In Situ Interaction Upgradation
Bo Yuan, Yifan Feng, Mengyan Ma, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
Kathleen J. Till, Mariah Abdullah, Tahera Alnassfan, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Yanping Yin, Paschalis Athanasiadis, Linda Karlsen, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 20, pp. 4444-4455
Open Access | Times Cited: 9
Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments
Hao Lei, Weiming Duan, San‐Qi Zhang, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106594-106594
Closed Access | Times Cited: 4
CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: from interconnected signalling pathways to therapeutic strategies
Brigitte Bauvois, Florence Nguyen‐Khac, Hélène Merle‐Béral, et al.
Biochimie (2024)
Closed Access | Times Cited: 1
Inhibiting PI3Kγ in acute myeloid leukemia
Aaron J. Stonestrom, Ross L. Levine
Nature Cancer (2024) Vol. 5, Iss. 7, pp. 958-959
Closed Access | Times Cited: 1
The Value of Neutrophil Gelatinase-Associated Lipocalin Receptor as a Novel Partner of CD38 in Chronic Lymphocytic Leukemia: From an Adverse Prognostic Factor to a Potential Pharmacological Target?
Brigitte Bauvois, Élise Chapiro, Claire Quiney, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2335-2335
Open Access | Times Cited: 3
Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma
Sarah Matarasso, Sarit Assouline
Future Oncology (2023) Vol. 19, Iss. 31, pp. 2083-2101
Closed Access | Times Cited: 3
Pirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Othman Al‐Sawaf, Min‐Hua Jen, Lisa M. Hess, et al.
Haematologica (2023)
Open Access | Times Cited: 3
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
Alberto J. Arribas, Sara Napoli, Luciano Cascione, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus
Folayemi Olayinka‐Adefemi, Sen Hou, Aaron J. Marshall
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ
Floyd Hassenrück, Maria Farina-Morillas, Lars Neumann, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 2
Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia
Maike Buchner
FEBS Letters (2024)
Closed Access
Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?
Marianne Ayoub, Santos A. Susín, Brigitte Bauvois
Cancers (2024) Vol. 17, Iss. 1, pp. 72-72
Open Access
Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia
Magdalena Witkowska, Agata Majchrzak, Paweł Robak, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 9, pp. 617-633
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top